Big Pharma | The Gillett Health Podcast #34

About this video

This episode examines how pharmaceutical money actually flows through modern medicine. Gillett and O’Hara argue the era of lavish perks for individual prescribers is largely over, replaced by modest lunches, research funding, and speaking fees, with advertising now the industry’s biggest influence channel. They discuss how health systems banning drug reps trade bias risk against losing samples and education, how little direct pharma presence exists in medical training, and why some approved drugs later prove harmful: short trials can miss problems that only emerge in post-marketing data. They close by disclosing their own position — no sponsors, frequent conflicted offers — and argue creators and clinicians alike should state conflicts of interest plainly.

Key takeaways

• The hosts argue following the money is still the best test of whether a clinician is compromised
• They claim extravagant prescriber perks are mostly historical; advertising is the modern influence channel
• Banning drug reps entirely has real downsides for samples and clinician education, they argue
• Post-marketing surveillance exists because short approval trials structurally miss delayed harms
• They hold up explicit conflict-of-interest disclosure as the standard patients should expect

Episode details: published May 8, 2023 · 409 views · 42:31 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.

← Previous: Hypothalamic Amenorrhea? | The Gillett Health podcast #32 · Next: The TRT Iceberg | [After Hours EP.7] →

All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)